After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...

Pancreatic cancer's neoadjuvant debate is no longer about whether systemic therapy matters. It is about when to give it. The field is split between clinicians who view preoperative treatment as the ...

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Abstracts Presented at ASCO 2026 In June 2026, Atossa Therapeutics, Inc. (NASDAQ: ATOS) announced that two abstracts were presented at the 2026 ...

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...

MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours. This is an ASCO Meeting ...

ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data. This episode, titled Integrating Durvalumab and ...

In a phase 2 trial of nonurothelial MIBC, half of patients receiving neoadjuvant chemoimmunotherapy showed no residual cancer at the time of surgery. The single-center, phase 2 trial included 17 ...